Innovative DCZCMC Platform: Dual Regulation of Cholesterol Dynamics and the cGAS/STING Pathway Activation to Combat Drug Resistance in Tumor Therapy
Small · 2025
DOI: 10.1002/smll.202509075 ↗Kurz gefasst
Fachartikel in der Zeitschrift Small, 2025. Verfasst von Jing Wang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, The First Affiliated Hospital of University of Science and Technology of China, Division of Life Sciences and Medicine, Univer…. Hauptthemen laut MEDLINE: Drug Resistance, Neoplasm, Cholesterol, Nucleotidyltransferases, Membrane Proteins. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 52 Literaturangaben.
Abstract (Originalsprache)
Chemoresistance remains a daunting challenge in bladder cancer therapy, primarily driven by cholesterol‐enriched rigid membranes that impede drug penetration and an immunosuppressive tumor microenvironment (TME) that evades immune surveillance. Herein, a biomimetic nanoplatform (DOX@COD‐ZCM@CS, DCZCMC) is reported engineered to orchestrate metabolic‐immunological crosstalk for synergistic reversal of chemoresistance. This integrated system comprises a Zn‐Co metal‐organic framework (Zn‐Co‐MOF, ZCM) core loaded with cholesterol oxidase (COD) and doxorubicin (DOX), surface‐functionalized with chondroitin sulfate (CS) for tumor‐specific targeting. Mechanistically, DCZCMC achieves three‐tiered synergism: 1) COD‐mediated cholesterol depletion (71.5% reduction, 111.2 vs 389.8 µ m in the saline group) disrupts membrane rigidity, augmenting intratumoral drug retention to 87% (vs 39% with free DOX); 2) ZCM converts COD‐generated H 2 O 2 into cytotoxic hydroxyl radicals (·OH), realizing pathological cholesterol‐to‐ reactive oxygen species (ROS) reprogramming for selective tumor oxidation; 3) Zn 2+ release triggers mitochondrial DNA (mtDNA) leakage, activating the cyclic GMP‐AMP synthase‐stimulator of interferon genes (cGAS‐STING) pathway to amplify interferon‐β (IFN‐β) and High Mobility Group Protein 1 (HMGB1) secretion, thereby driving dendritic cells (DCs) maturation and adaptive immune activation. In drug‐resistant xenografts, DCZCMC exhibits exceptional antitumor efficacy (95.6% tumor suppression) without systemic toxicity. This self‐amplifying “metabolic priming‐immune activation” cascade represents a paradigm shift in overcoming chemoresistance, offering a transformative strategy for bladder cancer and other malignancies characterized by metabolic‐immunological dysregulation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, The First Affiliated Hospital of University of Science and Technology of China, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, 230001, China.
- Department of Medicine, The First Affiliated Hospital of University of Science and Technology of China, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, 230001, China.
- Department of Surgery, The Affiliated Hospital of Qingdao University, Qingdao, 266003, China.
ORCID-Profile: Zhi Liu
Zitieren
APA
Wang, J., Fu, X., Zhang, H., & Liu, Z. (2025). Innovative DCZCMC Platform: Dual Regulation of Cholesterol Dynamics and the cGAS/STING Pathway Activation to Combat Drug Resistance in Tumor Therapy. Small. https://doi.org/10.1002/smll.202509075
Vancouver
Wang J, Fu X, Zhang H, Liu Z. Innovative DCZCMC Platform: Dual Regulation of Cholesterol Dynamics and the cGAS/STING Pathway Activation to Combat Drug Resistance in Tumor Therapy. Small. 2025. doi:10.1002/smll.202509075
BibTeX
@article{Wang2025,
author = {Wang, Jing and Fu, Xianchun and Zhang, Han and Liu, Zhi},
title = {Innovative DCZCMC Platform: Dual Regulation of Cholesterol Dynamics and the cGAS/STING Pathway Activation to Combat Drug Resistance in Tumor Therapy},
journal = {Small},
year = {2025},
doi = {10.1002/smll.202509075}
}
EUVIMED